PinCell is a biotechnology company targeting a novel pathway for the treatment of rare, severe dermatological diseases with high unmet medical need, through the development of a first-in-class, anti-apoptotic human anti-FasL mAb. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by world-class dermatology experts, is supported by an international Scientific Advisory Board and is led by a team of seasoned industry professionals and scientific researchers. PinCell’s lead program targets a rare autoimmune bullous disease called Pemphigus, which is characterized by blistering and erosions of the skin and mucous membranes. The condition is chronic, debilitating and potentially life-threatening. PinCell’s unique solution called PC111 was shown to inhibit the development of the typical skin blisters in in-vitro and ex-vivo human models of pemphigus, without suppressing the immune system (unlike current treatments). This is a central factor that makes our approach less prone to immune-related side effects, while providing an expected rapid onset of action, thus enabling patients to have a better quality of life. Additional rare disease research programs are underway in other dermatological diseases with high unmet medical need.